Table 2.
Relationship between response and transition of serum levels of carcinoembryonic antigen (CEA) and cytokine 19 fragment 21-1 (CYFRA 21-1).
| Case no. | Treatment response after 3 cycles | CEA (ng/mL) | CYFRA 21-1 (ng/mL) | ||
|---|---|---|---|---|---|
| Baseline | After 3 cycles | Baseline | After 3 cycles | ||
| 1 | CR | 178.6 | 21.3 | 3.4 | 2.3 |
| 2 | CR | 51.2 | 6.6 | 5.6 | 2.2 |
| 3 | PR | 9.4 | 6.4 | 109.0 | 3.7 |
| 4 | CR | 12.7 | 4.2 | 8.1 | 0.8 |
| 5 | SD | 8.7 | 6.5 | 8.0 | 2.2 |
| 6 | CR | 22.5 | 1.6 | 8.4 | 2.4 |
| 7 | SD | 150.9 | 3.0 | 28.8 | 1.3 |
| 8 | CR | 27.9 | 2.0 | 50.2 | 3.0 |
| 9 | PR | 5.1 | 1.7 | 3.3 | 0.8 |
| 10 | PR | 17.9 | 2.0 | 5.8 | 1.8 |
| 11 | PR | 68.2 | 4.3 | 8.2 | 1.1 |
| 12 | SD | 1.2 | 2.0 | 5.2 | 1.5 |
| 13 | PR | 226.9 | 7.9 | 10.8 | 2.0 |
The cutoff values; CEA 5.0 ng/mL, CYFRA21-1 3.5 ng/mL. All the cases with HER2 IHC 2 + in this study had HER2 gene amplification.
Abbreviations: CR, complete response; LNs, lymph nodes; PR, partial response; RR, response rate; SD, stable disease.